Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Inflation Reduction Act (IRA): ISPOR Key Takeaways
While attending the ISPOR US 2023 conference in Boston this year, Trinity team members had the opportunity to connect with industry colleagues, present original research, and participate in research panels and discussions regarding key industry trends. One top-of-mind industry topic for...
Blog
ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...
Blog
The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future
Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...
Blog
Highlights of the 2022 National Reimbursement Drug List (NRDL) Negotiation Outcome
Executive summary Highlight 1: Increased presence of multinational corporations in newly listed products from the 2022 NRDL negotiations The 2022 NRDL negotiations finished immediately before the week-long Chinese New Year holidays in January 2023, adding 83 novel non-traditional Chinese medicines...
Blog
From Customer Relationship Management to Providing Customers Quality Multi-Experience Engagements: What to Keep in Mind as You Embrace the Shift
Meet Melissa Leonhauser: Melissa has over 20 years of experience managing analytic solutions that support pharmaceutical brand teams. She has helped introduce and shape how pharmaceutical manufacturers use Real World Data to understand the patient journey and inform their decision...
Blog
Japan’s Latest Drug Pricing Policy Updates: Off-Year Revision and Other Anticipated Changes in 2023
Executive Summary: Introduction & History of the Regular Price Revisions in Japan For over two decades, Japan has maintained a biennial re-pricing approach in which drug prices are surveyed through wholesaler offices and healthcare institutions to capture the product discrepancy...
